Health News: [diabetes ]: Merck and Pfizer Agree to Develop Type 2 Diabetes Treatment

Yahoo! Health   |  My alerts   |   Edit Alert Monday, Apr 29, 2013 08:11 AM EDT

Health News : diabetes - News from Yahoo !   Merck, Pfizer to jointly develop diabetes drug Mon, 29 Apr, 2013 05:01 AM PDT (Reuters) - Drugmakers Pfizer Inc and Merck & Co Inc said they would jointly develop Pfizer's experimental type 2 diabetes drug, ertugliflozin, and expect late-stage trials to start later in 2013. Pfizer has so far received $60 million in upfront and milestone payments and will be eligible for addition... Continue reading Makanan mampu mengawal risiko diabetes Mon, 29 Apr, 2013 03:01 AM PDT 29 Apr – Penyakit kencing manis ialah suatu keadaan yang mana terdapatnya ketiadaan atau kekurangan penghasilan insulin, atau badan bersifat rintang terhadap insulin. Insulin ialah suatu hormon yang dihasilkan oleh pankreas. Continue reading

Health News : diabetes - Top images.

Health News : diabetes - News from other sources.   Merck and Pfizer Agree to Develop Type 2 Diabetes Treatment Mon, 29 Apr, 2013 05:10 AM PDT Merck and Pfizer Agree to Develop Type 2 Diabetes Treatment Continue reading Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at ... Mon, 29 Apr, 2013 04:53 AM PDT JERUSALEM, April 29, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type... Continue reading Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an ... Mon, 29 Apr, 2013 04:43 AM PDT WHITEHOUSE STATION, N.J. & NEW YORK--(BUSINESS WIRE)--Merck and Pfizer have entered into a collaboration agreement to develop and commercialize ertugliflozin, an investigational SGLT2 inhibitor being evaluated for the treatment of type 2 diabetes. Continue reading Diabetes, Cardiovascular and Renal Complications Mon, 29 Apr, 2013 03:36 AM PDT Set to double from $32bn to $64bn over the next 15 years, the global diabetes market is set for stellar growth as changing demographics and new therapies begin entering the clinic. Continue reading Living with type 1 diabetes Mon, 29 Apr, 2013 03:35 AM PDT Family life with type 1 diabetes Continue reading Portion-control Dinnerware Has Grown Up to Meet Today's Wellness Demands Mon, 29 Apr, 2013 03:09 AM PDT As the wellness industry grows to serve an overweight nation, one industry segment also continues to mature and develop. Portion-control tools have been proven effective for health issues such as obesity, diabetes, and weight control, and they can now be enjoyable to use. (PRWeb April 29, 2013) Read th... Continue reading Fearing for the future Mon, 29 Apr, 2013 03:03 AM PDT On Wednesday, the head of Diabetes UK, Richard Lane, will be in York to talk about how the disease is now one of the biggest burdens on the health of the individual, the nation and the NHS. In an exclusive interview with RICHARD CATTON, he dispels some of the myths and reveals some shocking truths abou... Continue reading Newly Discovered Hormone Could Yield New Treatment For Diabetes Mon, 29 Apr, 2013 02:52 AM PDT A breakthrough in helping the body to produce more insulin could make tedious injections of the hormone history. In type 2 diabetes, the body gradually loses its ability to make enough insulin to keep up with the sugar coming in from the diet. Eventually, the overwhelmed system leaves these sugars, in ... Continue reading

You received this email because you subscribed to Yahoo! Alerts. Use this link to unsubscribe from this alert. To change your communications preferences for other Yahoo! business lines, please visit your Marketing Preferences. To learn more about Yahoo!'s use of personal information, including the use of web beacons in HTML-based email, please read our Privacy Policy. Yahoo! is located at 701 First Avenue, Sunnyvale, CA 94089.